Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

New pre-clinical study with @WeickhardtOnc @ONJCRI showing dual targeting with an FGFR and ERBB3 inhibitor enhances the activity of FGFR inhibitors in FGFR3-driven bladder cancer. https://t.co/3ureg1t486

RT @WeickhardtOnc: Why doesn't FGFR inhibition lead to higher response rates in patients with FGFR3 alterations with met TCC? We've done so…

Why doesn't FGFR inhibition lead to higher response rates in patients with FGFR3 alterations with met TCC? We've done some in-vitro work that unsurprisingly shows that the Her3 pathway is a key mechanism of resistance: co-targeting Her3/FGFR is better http